Image pharmaphorum Editor Views & Analysis Digital success for pharma services in a uncertain world Laura Morrill from ECI Partners looks at why data and technology are the keys to success in pharma services post-COVID. Views & Analysis Providing a positive customer experience through pharma cont... Customers must be given positive, trustworthy, and relevant experiences, says Indegene’s Martin O’Brien. Views & Analysis A sea-change for pharma? Pandemic commercial models and laun... Sarah Rickwood looks at how COVID-19 is changing pharma’s commercial models and launch strategies. Views & Analysis 10 reasons why virtual collaboration and medical education w... While the effects of COVID-19 have been devastating for many industries, its positive impact on accelerating the uptake of digital health technologies and virtual collaboration solutions is Load more results
Views & Analysis Digital success for pharma services in a uncertain world Laura Morrill from ECI Partners looks at why data and technology are the keys to success in pharma services post-COVID.
Views & Analysis Providing a positive customer experience through pharma cont... Customers must be given positive, trustworthy, and relevant experiences, says Indegene’s Martin O’Brien.
Views & Analysis A sea-change for pharma? Pandemic commercial models and laun... Sarah Rickwood looks at how COVID-19 is changing pharma’s commercial models and launch strategies.
Views & Analysis 10 reasons why virtual collaboration and medical education w... While the effects of COVID-19 have been devastating for many industries, its positive impact on accelerating the uptake of digital health technologies and virtual collaboration solutions is
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
